Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Introduce Six GeneChip-Based Diagnostics Within 18 Months

NEW YORK, May 7 - A Roche official said today that the Swiss pharma giant will introduce six new diagnostic products over the next 18 months based on the Affymetrix GeneChip platform it licensed in January.


In a widely reported news conference in Switzerland, Heino von Prondzynski, the head of Roche's diagnostics division identified what tests the company plans to introduce into the market.


Initially, the company will roll out the AmpliChip CYP450 microarray for lab use in the US in May. The chip, designed by Roche and manufactured by Affymetrix, will be sold as an analyte-specific reagent.


Then, the company will also launch Affymetrix platform diagnostic tests for human papilloma virus, cystic fibrosis, colorectal cancer, HIV, and leukemia.


Roche officials were not available for comment.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.